ERJ open research
THE BEST IN OPEN ACCESS BASIC, TRANSLATIONAL & CLINICAL RESPIRATORY RESEARCH

Early View

Original research article

Lifetime cannabis exposure and small airway function in a population-based cohort study

Hua Shin Tan, Helena M. McAnally, Jack Dummer, Robert J. Hancox

Please cite this article as: Tan HS, McAnally HM, Dummer J, *et al*. Lifetime cannabis exposure and small airway function in a population-based cohort study. *ERJ Open Res* 2022; in press (https://doi.org/10.1183/23120541.00688-2021).

Lifetime cannabis exposure and small airway function in a population-based cohort study.

Hua Shin Tan[1], Helena M. McAnally[1], Jack Dummer[2], Robert J Hancox[1]

1. Department of Preventive & Social Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.
2. Department of Medicine, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

Correspondence: R. J. Hancox,

Telephone: +64 3 479 8512

E-mail: bob.hancox@otago.ac.nz

Word count: 3235

Running Head: Cannabis and small airways

Abstract (word count = 250)

Background and objective: The long-term effects of cannabis on small airway function remain unclear. We investigated associations between cannabis use and small airway function in a general population sample.

Methods: Cannabis use was ascertained at multiple ages from age 18 to 45 years and quantified as joint-years among 895 participants in the Dunedin Multidisciplinary Health and Development Study. Small airway function at ages 38 and 45 years was measured using impulse oscillometry before and after inhalation of salbutamol. Analyses used multiple linear regression adjusting for tobacco use, body mass index, and height. Longitudinal analyses of cannabis use between 38 and 45 years also adjusted for IOS at age 38.

Results: Lifetime cannabis joint-years with IOS differed between men and women: in women, cannabis use was associated with pre-bronchodilator R5, R20, X5, AX, and Fres and marginally associated with R5-R20. Cannabis use was not statistically significantly associated with any of the pre-bronchodilator IOS measures in men. Cannabis use between ages 38 and 45 was associated with a similar pattern of changes in IOS measures. After salbutamol, cannabis use was only statistically significantly associated with R5 and R20 among women and none of the IOS measures among men.

Conclusions: Cannabis use is associated with small airway dysfunction at age 45 years, indicating an increase in peripheral airway resistance and reactance. These associations were greater and only statistically significant among women. Associations were weaker and mostly non-significant after bronchodilator use suggesting that cannabis-induced changes in small airways may be at least partially reversible.

Introduction

Cannabis is the second most smoked substance and one of the most widely used recreational drugs in the world [1]. In New Zealand, 80% of New Zealanders have tried cannabis at least once by the age of 21 and 12% of the adult population report using cannabis in the past 12 months [2]. Despite the high prevalence of cannabis use, we do not understand the impact that it has on respiratory health. This is partly due to the illegal status of cannabis in many countries, making it difficult to study, and also because most cannabis users also smoke tobacco, making it difficult to distinguish the effects of cannabis from those of tobacco [3]. However, there is accumulating evidence that smoking cannabis has effects on lung function and respiratory symptoms [4-6].

Long term cannabis smoking has been associated with higher lung volumes measured as forced vital capacity (FVC) by spirometry with little change in forced expiratory volume in one second (FEV_1) in several studies, a pattern distinct from that of tobacco smoking [6-10]. The reasons for this difference between tobacco and cannabis are unknown and it raises the question of what other effects cannabis has on lung health. Little is known about the effect of cannabis on small airways (defined as airways with a diameter <2mm) [11]. Cannabis use has been associated with hyperinflation on both lung function tests and CT scans, which could reflect small airways dysfunction, suggesting that further investigation of the effect of cannabis on small airways is needed [12].

One way of investigating peripheral airway function is to use impulse oscillometry (IOS) to measure respiratory impedance using sound waves, at frequencies typically of 4-30Hz, superimposed upon tidal breathing [13, 14]. Impedance comprises resistance and reactance. Resistance provides information regarding the forward pressure of the conducting airways from the mouth to the respiratory bronchi [15]. Sound waves of lower frequency travel

deeper into the lung than those of higher frequency, hence resistance at 5Hz (R5) and 20 Hz (R20) reflect total and central airway obstruction respectively, while the difference between R5 and R20 (R5-R20) reflects peripheral airway obstruction, and is a measure of small airways narrowing [16]. Reactance captures both the elastic properties of the small airways, known as capacitance, and the forces of the moving air through the airways, known as inertance [15]. At lower frequencies, capacitance is the more dominant component of reactance, hence reactance at 5Hz (X5) provides information regarding the capacitive or elastic energy of the small airways. The frequency at which the magnitude of the capacitive and inertance are the same is known as resonant frequency (Fres). The area of reactance (AX) represents the sum of reactance at all frequencies between 5 Hz and Fres [17]. These IOS measures are believed to be altered by small airway disease, and correlate with other measures of small airway dysfunction in patients with asthma [18, 19], exacerbations [20] and response to inhaled corticosteroids [21].

In an exploratory investigation into the determinants of peripheral airway function in 38 year-olds in the Dunedin Multidisciplinary Health and Development Study (a birth cohort of 1037 individuals born in 1972/1973), lifetime history of cannabis consumption was associated with multiple IOS parameters (R5, R20, R5-20, X5, AX, and Fres) in women and R5-20 and X5 in men [22]; however, age 38 is still early for the development of smoking-related lung diseases and we are not aware of any other investigations of IOS and cannabis use. We therefore investigated if the relationship between cannabis use and peripheral airways function measured by IOS persists up to the age of 45, whether cannabis use between 38 and 45 was associated with changes in IOS, and investigated if these associations differed by sex.

Methods

Participants are members of the Dunedin Multidisciplinary Health and Development Study, a longitudinal study of the health and behaviour of a complete cohort of individuals born in Dunedin, New Zealand in 1972/1973 [22, 23]. At age 3 years 1037 individuals (52% male; 91% of eligible births) participated in the assessment, forming the base sample for the study. Study members represent the full range of socioeconomic status in the general population of the South Island of New Zealand and are primarily of New Zealand/European ethnicity. The cohort has been assessed at ages 3, 5, 7, 9, 11, 13, 15, 18, 21, 26, 32, 38, and most recently at 45 years when we assessed 938 of 997 surviving participants (94%). Respiratory information, including asthma diagnoses, has been obtained at each assessment from 9 years onwards. Childhood socio-economic status was based on the income and education associated with the occupation of parents, assessed repeatedly from birth to age 15 on a 6-point scale (1=high) as previously reported [24]. Adult SES was assessed on a similar scale based on the participants' occupation at age 45. The Dunedin Study was approved by the Health and Disability Ethics Committee, Ministry of Health, New Zealand. Study members gave informed consent before participating.

Cannabis smoking history was obtained at ages 18, 21, 26, 32, 38, and 45 years [25]. At each assessment, participants were asked how many times they had used marijuana in the previous year. Cumulative exposure to cannabis was calculated as the number of "joint-years" since age 17, whereby using cannabis once a day for a year is equivalent to one joint-year. These estimates assume that the number of times marijuana had been used in the previous year was representative of all years since the previous assessment. At ages 38 and 45, the maximum recorded use in the previous year was capped at 365 (i.e. once a day). Therefore, maximum

use was truncated to one joint year each year (i.e. the maximum possible between age 17 and 45 year was recorded at 28 joint years). Cumulative tobacco exposure was calculated from the reported number of cigarettes smoked per day up to 18 years, and between each of the assessments up to age 45 years. Where data were not collected for an assessment, the amount of cannabis or tobacco smoked reported at the next assessment was used to calculate cumulative exposure. One pack-year is defined as the equivalent of 20 cigarettes a day for one year. Those who had smoked less than 1 cigarette a day for a year, and less than 20 packets in their lifetime were regarded as non-smokers [26].

At age 45 years, IOS was measured using the Jaeger MasterScreen Impulse Oscillometry system (Jaeger, Wurzburg, Germany), with a recording based on five impedance spectra (five impulses) per second. Subjects wore nose clips, with their face supported to decrease the shunt compliance of the cheeks. A single technically-acceptable recording (free of artefacts caused by coughing, breath holding, swallowing, or vocalization) was performed during stable tidal breathing for a 30s interval through a mouthpiece and bacterial filter. IOS parameters included R5, R20, R5-R20, X5, AX and Fres. Pre-bronchodilator IOS was measured before spirometry or any forced exhalation measures, but after measurements of exhaled breath, which involved deep inhalations. IOS was repeated 15 – 20 minutes after 200mcg salbutamol, administered using a large volume spacer. The post-bronchodilator measurements took place after spirometry and body plethysmograph measurements. All equipment was calibrated daily. Height and weight were measured in light clothing without shoes to calculate BMI in kg/m^2.

Statistical analysis

R5, R20, R5-R20, X5, AX and Fres were transformed using natural logarithms to achieve a parametric distribution. By convention, X5 values are negative, so were first converted to positive values to permit log-transformation. Differences between pre- and post-salbutamol values were evaluated using paired t-tests. Multivariable linear regression was used to assess the independent associations of joint-years of cannabis and pack-years smoking with each measure of IOS adjusting for height, BMI, and sex. Because analyses at 38 years had found that cannabis was more strongly associated with IOS parameters in women than men, sex interaction terms were fitted [22]. A small number of other individuals had extreme IOS values that influenced the initial analyses: those with IOS values more than 5 SDs from the mean (after log transformation) were excluded from the analyses of pre- (n=1) and post-salbutamol (n=2) IOS values. Otherwise, all available data were included in each analysis and missing data were assumed to be missing at random. The final regression models were checked by inspection of scatterplots of residuals against continuous predictors and fitted values.

To assess whether change in cannabis use was associated with change in IOS measures, the joint years estimated between age 38 and 45 (based on the amount reported at 45) was used as the main predictor in analyses of IOS measures at 45 with adjustments for the IOS measure at 38, tobacco use between 38 and 45, height, and BMI at 45.

Analyses used Stata 15.1 (Stata Corporation, College Station, TX, USA). P values ≤ 0.05 were considered statistically significant. No adjustments were made for multiple testing.

Results

Sufficient exposure and outcome data for analysis were available for 895 participants. More men had used cannabis than women (79% and 65% respectively, $p<0.001$). Women were slightly more likely to have smoked tobacco than men (52% and 50% respectively), although this difference was not statistically significant. Median cannabis and tobacco use and BMI are shown in Table 1. Childhood-onset asthma (a diagnosis reported by age 15) was not associated with subsequent cannabis or tobacco use indicating that participants with asthma were not less likely to avoid smoking these substances. At age 45, 141 women (31%) and 135 men (30%) reported having had asthma at some time in their lives, while 93 women (21%) and 79 men (17%) had current asthma with symptoms or treatment in the past year.

The geometric means for all IOS values by sex are shown in Table 2. There were statistically significant differences in the mean log-transformed values between before and after bronchodilator (all p values <0.001 by paired t-tests; Supplementary Table 1). IOS measures according to categories of smoking history (never, cannabis only, tobacco only, or both cannabis and tobacco) are shown in Supplementary Table 2. Most IOS measures were moderately or strongly correlated with each other (Supplementary Tables 3 and 4).

After adjustment for pack-years, BMI and height, cannabis joint years were associated with pre-salbutamol R5, R5-R20, X5, AX and Fres, but were not significantly associated with R20 (Table 3).

The interaction term for sex by cannabis joint-years was tested for each of the IOS parameters. Several of the interaction terms were statistically significant for the pre-salbutamol measures, so the results are also presented separately by sex (Table 3). In women,

cannabis was statistically significantly associated with pre-salbutamol R5, R20, X5, AX, and Fres. The association with R5-R20 did not reach formal statistical significance (p=0.059). In men, cannabis was not statistically significantly associated with any of the pre-salbutamol IOS measures (Table 4). After salbutamol use, cannabis use was only statistically significantly associated with R5 and R20 among women and not statistically associated with IOS measures among men.

The pattern of associations between pack-years tobacco use and IOS measures was quite different to that for joint-years of cannabis. Whereas cannabis joint-years were associated with a wide range of pre-bronchodilator, but not post-salbutamol, IOS measures in women, tobacco pack-years were only associated with pre-salbutamol R5-R20 in women but were associated with several IOS measures in both sexes after salbutamol (Supplementary Tables 5 and 6).

In the longitudinal analyses adjusting for IOS measures at 38, the amount of cannabis use reported at age 45 was associated with R5, X5, AX, and Fres among women at 45 (Table 5 and 6), whereas the amount of tobacco reported at age 45 was not associated with any IOS measure. For men, the amount of cannabis use was not associated with IOS measures in these analyses, whereas tobacco use was associated with higher values for X5, but no other measures.

In analyses restricted to participants who had never smoked tobacco, there were no statistically significant associations between cannabis use and IOS measures in the whole sample (Supplementary Table 7) or when stratified by sex (not shown). Adjusting for

childhood and adult socio-economic status or excluding those who had ever reported asthma also provided similar results (Supplementary Tables 8 and 9).

Discussion

We have found that lifetime cannabis use is associated with multiple IOS measures of small airway dysfunction at age 45 years suggesting that cannabis smoking leads to increases in peripheral airway resistance and reactance. The associations of cannabis use with IOS measures were stronger and only statistically significant among women, and were weaker and mostly non-significant after bronchodilator use. Longitudinal analyses of cannabis use since age 38, which adjusted for the same IOS measure at 38, confirmed that cannabis use was associated with multiple IOS measures of pre-bronchodilator airway dysfunction among women, but not among men.

Consistent with findings from an analysis of IOS measures at age 38 and several studies of other lung function measures[10], cannabis had a different pattern of associations to tobacco. Among the pre-salbutamol IOS measures, lifetime history of tobacco smoking was only statistically associated with R5-R20 (Table 3), but tobacco smoking was associated with all post-salbutamol IOS measures when men and women were analysed together and several of the measures in each sex when they were analysed separately (Supplementary Tables 5 and 6). By contrast, the associations between cannabis use and IOS measures were weaker and mostly non-significant after salbutamol use, suggesting that cannabis-induced changes in the small airways may be at least partially reversible. These reasons for these differences are not clear, but confirm that cannabis and tobacco appear to have distinct effects on small airways as well as different effects on measures of large airway function. We did not find associations

between cannabis use and IOS measures in never tobacco smokers however (Supplementary Table 7), but this may have been because the amount of cannabis used by never tobacco smokers tended to be very low (median 0.008 joint-years compared to 0.41 joint-years for ever tobacco smokers).

The finding that cannabis was associated with pre-bronchodilator but not post-bronchodilator IOS measures raises the question of whether asthma could influence the observed associations. In fact, childhood-onset asthma (by age 15) was not associated with adult cannabis or tobacco use indicating that these participants did not avoid smoking either substance and, therefore, asthma is not a confounder of the analyses. Since cannabis use has been shown to cause respiratory symptoms, cannabis could lead to a diagnosis of late-onset "asthma" or cause an asthma-like syndrome. There was a weak association between joint-years and asthma at age 45 (Odds Ratio 1.035), which was statistically significant in men but not women. A *post-hoc* analysis adjusting for asthma diagnoses at age 45 made no material difference to the findings, however (data not shown).

Cannabis was associated with a broader range of IOS associations in women than men. Most of the sex-interaction terms were significant for pre-bronchodilator IOS measures indicating that these sex differences in the associations were statistically significant. These findings are similar to an exploratory analysis of multiple determinants of IOS at age 38 in this cohort, when we found a broader association between cannabis use and IOS parameters in women than men. They extend the findings of the earlier study by adding a longitudinal analysis, which supports the findings of the cross-sectional analyses. Why these sex differences occur is not clear, particularly as women tend to use less cannabis than men. It is possible that baseline differences in lung size, and therefore the small airways could explain a difference in

susceptibility. There may also be more generalised differences in the susceptibility of men and women to the effects of cannabis: a human laboratory study of the acute effects of smoked cannabis on young adults found that women lower cannabis doses to experience the same subjective and physiological effects as men [27]. There is also some evidence that the hormone oestradiol could increase the susceptibility of women to COPD [28] and it is possible that this hormone also influences the effect of cannabis smoke on small airways.

The clinical implications of our findings are not yet clear, but the published literature and current findings (Supplementary Tables 3 and 4) show that these IOS measures correlate with one another and are all associated with small airways function [29]. Our findings are also consistent with several animal models on the long-term effects of inhaled cannabis on small airways (10). In rhesus monkeys, for example, a direct relationship was found between the amount of cannabis smoke inhaled and the severity and frequency of inflammatory damage visible in the small airways on histopathological examination [30]. However, due to the difficulty of examining small airway pathology in humans and the confounding effects of tobacco use in many human studies, the exact mechanisms of cannabis effects on human small airways are unknown. Given that studies have consistently found that cannabis use is associated with large airway conductance (including among these participants),[10] it is surprising that R20 (an IOS measure of central airway function) was not associated with cannabis in men. The reasons for this apparent discrepancy are unknown.

The study has a number of strengths as a longitudinal study with prospective collection of cannabis and tobacco exposure at several ages from age 18 to 45 years with a high rate of follow-up. A limitation of the study is that because of time constraints, only single measures of IOS before and after bronchodilator were taken rather than the recommended three

measurements.[31] Although this may have led to measurement errors, the effect of these errors would be likely to bias any association towards the null. Another source of error will be from the self-report of cannabis and tobacco use and the assumption that past-year cannabis use was representative of all of the years between assessments. These measurement errors would also be likely to bias the estimates of associations towards the null, however, there could be residual confounding of the association between cannabis or tobacco and IOS if exposure to the other substance was not accurately measured. *Post hoc* adjustment for childhood and adult socio-economic status or excluding those with a history of asthma did not change the pattern of findings (Supplementary Tables 8 and 9). We have not assessed other potential confounders such as environmental smoke or pollution exposure. As an exploratory analysis of patterns of IOS association with cannabis, we analysed a large number of associations but have not adjusted the analyses for multiple comparisons. Therefore the findings for individual analyses should be interpreted cautiously.

Although the effects of cannabis on the lungs remain poorly understood, this analysis adds to the evidence that smoking cannabis does have an impact on lung function and respiratory health [10], and indicates that these effects are different to those of tobacco. While the clinical consequences of prolonged exposure of the lungs to cannabis are still uncertain, the accumulating evidence of harm should be considered in policies concerned with cannabis use and harm-reduction. We need more epidemiological and pathophysiological research on the effects of cannabis on small airways and lung function. In particular, we need to understand why there appear to be sex differences in effects of cannabis smoking on small airways.

In conclusion, lifetime cannabis exposure is associated with measures of small airways dysfunction indicating higher small airway resistance and greater reactance. These

associations appear to be stronger in women than men. The findings indicate that that the peripheral airways may be a site where cannabis-associated damage differs from the effects of tobacco.

Acknowledgements

We thank the Dunedin Study members and their families and friends for their long-term involvement, and study founder, Dr Phil A Silva. We also thank the Dunedin Unit Director, Professor Richie Poulton, the Unit Staff, and Professor Malcom Sears who started the respiratory theme. Professors Terrie Moffitt and Avshalom Caspi collected the cannabis data used in this report. The Dunedin Multidisciplinary Health and Development Research Unit is funded by the Health Research Council of New Zealand (programme grant 16-604) and has also received funding from the New Zealand Ministry of Business, Innovation and Employment. This research was also supported by UK MRC grant MR/P005918/1 and US-National Institute of Aging grants R01AG032282 and RO1AG069936. The funders played no role in the conduct of the study or the decision to publish the findings.

References

1. World Drug Report 2020. United Nations Publication: Sales No. E.20.XI.6; 2020.

2. NZ Drug Foundation. Drugs in NZ - an Overview. [cited 2021; Available from: https://www.drugfoundation.org.nz/policy-and-advocacy/drugs-in-nz-an-overview/

3. Lange P. Cannabis and the Lung. *Thorax* 2007: 62: 1036-1037.

4. Rooke SE, Norberg MM, Copeland J, Swift W. Health outcomes associated with long-term regular cannabis and tobacco smoking. *Addictive Behaviors* 2013: 38: 2207-2213.

5. Taylor DR, Fergusson DM, Milne BJ, Horwood LJ, Moffitt TE, Sears MR, Poulton R. A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults. *Addiction* 2002: 97: 1055-1061.

6. Hancox RJ, Poulton R, Ely M, Welch D, Taylor DR, McLachlan CR, Greene JM, Moffitt TE, Caspi A, Sears MR. Effects of cannabis on lung function: a population-based cohort study. *Eur Respir J* 2010: 35: 42-47.

7. Kempker JA, Honig EG, Martin GS. The effects of marijuana exposure on expiratory airflow. A study of adults who participated in the U.S. National Health and Nutrition Examination Study. *Ann Am Thor Soc* 2015: 12: 135-141.

8. Macleod J, Robertson R, Copeland L, McKenzie J, Elton R, Reid P. Cannabis, tobacco smoking, and lung function: A cross-sectional observational study in a General Practice population. *Br J Gen Pract* 2015: 65: e89-e95.

9. Tashkin DP. Effects of marijuana smoking on the lung. *Ann Am Thor Soc* 2013: 10: 239-247.

10. Gracie K, Hancox RJ. Cannabis use disorder and the lungs. *Addiction* 2020.

11. Santus P, Radovanovic D, Pecchiari M, Ferrando M, Tursi F, Patella V, Braido F. The relevance of targeting treatment to small airways in asthma and COPD. *Respir Care* 2020: 65: 1392-1412.

12. Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, Robinson G, Beasley R. Effects of cannabis on pulmonary structure, function and symptoms. *Thorax* 2007: 62: 1058-1063.

13. Bickel S, Popler J, Lesnick B, Eid N. Impulse oscillometry: Interpretation and practical applications. *Chest* 2014: 146: 841-847.

14. Brashier B, Salvi S. Measuring lung function using sound waves: role of the forced oscillation technique and impulse oscillometry system. *Breathe* 2015: 11: 57-65.

15. Bednarek M, Grabicki M, Piorunek T, Batura-Gabryel H. Current place of impulse oscillometry in the assessment of pulmonary diseases. *Respir Med* 2020: 105952-105952.

16. Foy BH, Soares M, Bordas R, Richardson M, Bell A, Singapuri A, Hargadon B, Brightling C, Burrowes K, Kay D, Owers-Bradley J, Siddiqui S. Lung Computational Models and the Role of the Small Airways in Asthma. *Am J Respir Crit Care Med* 2019: 200: 982-991.

17. Lundblad LKA, Siddiqui S, Bossé Y, Dandurand RJ. Applications of oscillometry in clinical research and practice. *Can J Respir Crit Care Sleep Med* 2019: 1-15.

18. Postma DS, Brightling C, Baldi S, Van den Berge M, Fabbri LM, Gagnatelli A, Papi A, Van der Molen T, Rabe KF, Siddiqui S, Singh D, Nicolini G, Kraft M, Pizzichini E, Cukier A, Stelmach R, Olivenstein R, Zhang Q, Badorrek P, Gessner C, Scichilone N, Chetta A, Paggiaro P, Milleri S, D'Amato M, Spanevello A, Foschino MP, Boersma WG, Broeders M, Vroegop JS, Plaza Moral V, Djukanovic R, Usmani O, Schilz R, Martin R, Hanania N. Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study. *Lancet Respir Med* 2019: 7: 402-416.

19. Williamson PA, Clearie K, Menzies D, Vaidyanathan S, Lipworth BJ. Assessment of small-airways disease using alveolar nitric oxide and impulse oscillometry in asthma and COPD. *Lung* 2011: 189: 121-129.

20. Gonem S, Umar I, Burke D, Desai D, Corkill S, Owers-Bradley J, Brightling CE, Siddiqui S. Airway impedance entropy and exacerbations in severe asthma. *Eur Respir J* 2012: 40: 1156-1163.

21. Hozawa S, Terada M, Hozawa M. Comparison of budesonide/formoterol Turbuhaler with fluticasone/salmeterol Diskus for treatment effects on small airway impairment and airway inflammation in patients with asthma. *Pulmonary Pharmacol Ther*: 24: 571-576.

22. Robinson PD, King GG, Sears MR, Hong CY, Hancox RJ. Determinants of peripheral airway function in adults with and without asthma. *Respirology* 2017: 22: 1110.

23. Poulton R, Moffitt TE, Silva PA. The Dunedin Multidisciplinary Health and Development Study: overview of the first 40 years, with an eye to the future. *Soc Psychiatry Psychiatr Epidemiol* 2015: 50: 679-693.

24. Hancox RJ, Milne BJ, Taylor DR, Greene JM, Cowan JO, Flannery EM, Herbison GP, McLachlan CR, Poulton R, Sears MR. Relationship between socioeconomic status and asthma: a longitudinal cohort study. *Thorax* 2004: 59: 376-380.

25. Thomson WM, Poulton R, Broadbent JM, Moffitt TE, Caspi A, Beck JD, Welch D, Hancox RJ. Cannabis smoking and periodontal disease among young adults. *JAMA* 2008: 299: 525-531.

26. Ferris BG. Epidemiology Standardization Project (American Thoracic Society). *Am Rev Respir Dis* 1978: 118: 1-120.

27. Matheson J, Sproule B, Di Ciano P, Fares A, Le Foll B, Mann RE, Brands B. Sex differences in the acute effects of smoked cannabis: evidence from a human laboratory study of young adults. *Psychopharmacol* 2020: 237: 305-316.

28. Tam A, Tanabe N, Churg A, Wright JL, Hogg JC, Sin DD. Sex differences in lymphoid follicles in COPD airways. *Respir Res* 2020: 21: 46-46.

29. Díaz Palacios MÁ, Hervás Marín D, Giner Valero A, Colomer Hernández N, Torán Barona C, Hernández Fernández de Rojas D. Correlation between impulse oscillometry parameters and asthma control in an adult population. *J Asthma allergy* 2019: 12: 195-203.

30. Fligiel SEG, Beals TF, Tashkin DP, Paule MG, Scallet AC, Ali SF, Bailey JR, Slikker W. Marijuana exposure and pulmonary alterations in primates. *Pharmacol Biochem Behav* 1991: 40: 637-642.

31. King GG, Bates J, Berger KI, Calverley P, de Melo PL, Dellacà RL, Farré R, Hall GL, Ioan I, Irvin CG, Kaczka DW, Kaminsky DA, Kurosawa H, Lombardi E, Maksym GN, Marchal F, Oppenheimer BW, Simpson SJ, Thamrin C, van den Berge M, Oostveen E. Technical standards for respiratory oscillometry. *Eur Respir J* 2020: 55: 1900753.

Table 1: Descriptive values

	Whole Sample		Women		Men	
	Median	Range	Median	Range	Median	Range
Cannabis Use (Joint Years)	0.08	0-28	0.03	0-26.45	0.17	0-28
Cannabis Use (non-Tobacco Users Only)	0.01	0-28	0	0-19.32	0.03	0-28
Cannabis Use (Tobacco and Cannabis Users Only)	0.62	0.003-27.97	0.23	0.003-26.45	2.12	0.003-27.97
Tobacco Use (Pack Years)	0.11	0-51.03	0.25	0-41.41	0	0-51.03
BMI (kg/m^2)	27.6	16.2-62.2	27.1	16.2-62.2	27.8	19.0-47.5
Childhood SES	3.3	1-6	3.3	1-6	3.3	1-6
Adulthood SES	4	1-6	4	1-6	4	1-6

SES (Socio-economic status) is on a 1-6 scale with 1 representing the highest SES. Childhood SES is based on parental occupations between birth and age 15. Adult SES is based on occupation at age 45.

Table 2: Pre-bronchodilator IOS values at age 45 years

		Women				Men			
		n	Mean	95% CI		*n*	Mean	95% CI	
R5	cm.H_2O/L/s	*441*	5.17	5.00	5.35	*454*	4.49	4.34	4.64
R20	cm.H_2O/L/s	*441*	4.15	4.01	4.28	*454*	3.65	3.54	3.77
R5-R20	cm.H_2O/L/s	*441*	1.03	0.94	1.13	*454*	0.84	0.76	0.84
X5	cm.H_2O/L/s	*440*	-1.60	-1.69	-1.50	*454*	-1.19	-1.26	-1.12
Ax	cm.H_2O/L/s	*437*	6.99	6.32	7.67	*449*	4.86	4.35	5.37
Fres	Hz	*440*	14.29	13.81	14.77	*452*	13.06	12.61	13.51

Means are geometric means of raw IOS values. The *n* values differ slightly because of missing data. R5=resistance at 5Hz, R20=resistance at 20Hz, R5-R20= difference between R5 and R20, X5= reactance at 5Hz, AX= area under the reactance curve between 5 and Fres, Fres= Resonant frequency.

Table 3: Adjusted associations of cannabis and tobacco with pre-bronchodilator IOS measures for the whole sample

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
	n	877	877	877	876	868	870
Joint Years	*β*	**0.104**	0.073	**0.086**	**0.110**	**0.130**	**0.133**
	95% CI	*0.033-0.175*	*-0.001-0.148*	*0.013-0.158*	*0.039-0.174*	*0.060-0.200*	*0.062-0.204*
	p	*0.004*	*0.054*	*0.020*	*0.002*	*<0.001*	*<0.001*
Pack Years	*β*	0.042	0.003	**0.076**	0.041	0.052	0.047
	95% CI	*-0.029-0.113*	*-0.072-0.077*	*0.004-0.149*	*-0.027-0.108*	*-0.018-0.123*	*-0.025-0.119*
	p	*0.248*	*0.946*	*0.039*	*0.237*	*0.147*	*0.197*
Interaction term[b]	*p*	***0.031***	*0.131*	***0.034***	*0.062*	***0.034***	*0.054*

[a] All IOS measures are log-transformed and analyses are adjusted for use of both substances and also adjusted for sex, BMI, and height; bolded values are statistically significant. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

[b] Interaction term p-values are for joint years by sex in the adjusted model for each IOS measure tested for after the adjusted model was run

Table 4: Adjusted associations of cannabis and tobacco with pre-bronchodilator IOS measures stratified by sex

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
Women	*n*	434	434	434	433	430	432
Joint-years	*β*	**0.187**	**0.150**	0.137	**0.234**	**0.240**	**0.222**
	95%CI	*0.058-0.315*	*0.014-0.286*	*-0.007-0.281*	*0.109-0.358*	*0.116-0.364*	*0.095-0.350*
	p	*0.004*	*0.030*	*0.061*	*<0.001*	*<0.001*	*0.001*
Pack-years	*β*	0.058	-0.005	**0.139**	-0.038	0.015	0.030
	95% CI	*-0.058-0.175*	*-0.128-0.119*	*0.009-0.270*	*-0.151-0.075*	*-0.098-0.128*	*-0.086-0.146*
	p	*0.327*	*0.940*	*0.037*	*0.510*	*0.796*	*0.612*
Men	*n*	443	443	443	443	438	438
Joint-years	*β*	0.070	0.042	0.066	0.053	0.083	**0.094**
	95% CI	*-0.015-0.156*	*-0.047-0.132*	*-0.011-0.143*	*-0.026-0.113*	*-0.003-0.168*	*0.009-0.179*
	p	*0.107*	*0.351*	*0.095*	*0.186*	*0.058*	*0.030*
Pack-years	*β*	0.024	<0.001	0.032	0.079	0.067	0.051
	95% CI	*-0.066-0.114*	*-0.095-0.094*	*-0.049-0114*	*-0.005-0.163*	*-0.024-0.158*	*-0.040-0.142*
	p	*0.599*	*0.996*	*0.437*	*0.064*	*0.150*	*0.272*

[a] All IOS measures transformed and analyses are adjusted for use of both substances and also adjusted for BMI and height; significant associations are bolded. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

Table 5: Longitudinal analyses of cannabis and tobacco use between ages 38 and 45 with pre-bronchodilator IOS measures for the whole sample

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
	n	864	864	864	862	856	857
Joint Years	*β*	**0.078**	0.060	0.043	**0.059**	**0.076**	**0.091**
38-45	*95% CI*	*0.023-0.132*	*-0.002-0.121*	*-0.014-0.100*	*0.003-0.114*	*00.23-0.129*	*0.037-0.145*
	p	*0.005*	*0.056*	*0.140*	*0.038*	*0.005*	*0.001*
Pack Years	*β*	0.017	-0.004	0.044	0.048	0.037	0.015
38-45	*95% CI*	*-0.038-0.072*	*-0.066-0.058*	*-0.014-0.101*	*-0.009-0.104*	*-0.016-0.091*	*-0.040-0.069*
	p	*0.553*	*0.903*	*0.134*	*0.099*	*0.173*	*0.601*

[a] All IOS measures are log-transformed. Analyses are adjusted for use of both substances and also adjusted for sex, BMI, height, and the relevant IOS measure at age 38 (e.g., R5 at 38 is the adjustment for age 45 R5); bolded values are statistically significant. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

Table 6: Longitudinal analyses of cannabis and tobacco use between ages 38 and 45 with pre-bronchodilator IOS measures stratified by sex

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
Women	n	426	426	426	425	422	423
Joint-years	*β*	**0.125**	0.075	0.085	**0.125**	**0.140**	**0.129**
38-45	*95% CI*	*0.035-0.214*	*-0.025-0.176*	*-0.019-0.189*	*0.035-0.218*	*0.054-0.226*	*0.042-0.217*
	p	*0.006*	*0.142*	*0.109*	*0.008*	*0.001*	*0.004*
Pack-years	*β*	0.002	-0.007	0.077	-0.064	-0.017	0.013
38-45	*95% CI*	*-0.107-0.111*	*-0.129-0.115*	*-0.049-0.203*	*-0.176-0.047*	*-0.121-0.087*	*-0.093-0.120*
	p	*0.972*	*0.906*	*0.232*	*0.258*	*0.749*	*0.804*
Men	n	438	438	438	437	434	434
Joint-years	*β*	0.049	0.049	0.015	0.023	0.039	0.066
38-45	*95% CI*	*-0.019-0.117*	*-0.029-0.127*	*-0.047-0.077*	*-0.045-0.091*	*-0.028-0.107*	*-0.003-0.135*
	p	*0.158*	*0.214*	*0.644*	*0.510*	*0.255*	*0.062*
Pack-years	*β*	0.025	<0.001	0.034	**0.093**	0.060	0.017
38-45	*95% CI*	*-0.038-0.088*	*-0.073-0.073*	*-0.023-0.091*	*0.029-0.157*	*-0.003-0.122*	*-0.047-0.081*
	p	*0.432*	*0.999*	*0.242*	*0.005*	*0.063*	*0.601*

[a] All IOS measures are log-transformed and analyses are adjusted for use of both substances and also adjusted for BMI, height, and the relevant IOS measure at age 38 (e.g., R5 at 38 is the adjustment for age 45 R5); statistically significant associations are bolded. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years

Lifetime cannabis exposure and small airway function in a population-based cohort study

Hua Shin Tan, Helena M. McAnally, Jack Dummer, Robert J Hancox

Online supplement

Supplementary Table 1: Post-bronchodilator IOS values at age 45 years

	Women				Men			
	n	Mean	95% CI		*n*	Mean	95% CI	
R5	*440*	4.15	4.02	4.29	*453*	3.68	3.56	3.79
R20	*440*	3.54	3.43	3.65	*453*	3.22	3.12	3.32
R5-R20	*440*	0.61	0.55	0.68	*453*	0.46	0.41	0.50
X5	*439*	-2.16	-2.66	-1.64	*452*	-1.37	-1.61	-1.13
Ax	*434*	3.49	3.18	3.80	*444*	2.38	2.10	2.67
Fres	*438*	11.40	11.07	11.75	*451*	10.32	10.01	10.64

Note: means are geometric means of raw IOS values. The *n* values differ slightly because of missing data. R5=resistance at 5Hz, R20=resistance at 20Hz, R5-R20= difference between R5 and R20, X5= reactance at 5Hz, AX= area under the reactance curve between 5 and Fres, Fres= Resonant frequency.

Supplementary Table 2: Pre-bronchodilator IOS values at age 45 years by smoking status.

	Women				Men			
Never smokers	*n*	Mean	95% CI		*n*	Mean	95% CI	
R5	*110*	5.02	4.71	5.33	*82*	4.22	3.87	4.58
R20	*110*	4.05	3.81	4.30	*82*	3.47	3.16	3.79
R5-R20	*110*	0.96	0.80	1.12	*82*	0.75	0.62	0.89
X5	*110*	-1.50	-1.64	-1.36	*82*	-1.05	-1.16	-0.93
Ax	*110*	6.46	5.39	7.57	*81*	4.26	3.36	5.20
Fres	*110*	14.07	13.18	14.97	*81*	12.97	11.98	13.99
Cannabis users only								
R5	*99*	5.17	4.79	5.55	*145*	4.43	4.16	4.70
R20	*99*	4.18	3.88	4.48	*145*	3.62	3.42	3.83
R5-R20	*99*	1.00	0.82	1.17	*145*	0.82	0.68	0.95
X5	*98*	-1.57	-1.73	-1.42	*145*	-1.18	-1.31	-1.06
Ax	*98*	6.66	5.52	7.85	*145*	4.67	3.77	5.60
Fres	*99*	14.57	13.60	15.56	*145*	12.89	12.16	13.63
Tobacco users only								
R5	*40*	5.07	4.59	5.57	*10*	5.56	3.58	7.70
R20	*40*	4.01	3.65	4.39	*10*	4.04	3.26	4.85
R5-R20	*40*	1.05	0.72	1.39	*10*	1.55	0.06	3.15
X5	*40*	-1.63	-2.00	-1.26	*10*	-1.95	-3.45	-0.31
Ax	*40*	6.93	4.46	9.65	*10*	9.36	1.22	20.63
Fres	*40*	14.15	12.62	15.75	*10*	15.34	10.61	20.80
Cannabis & Tobacco users								
R5	*191*	5.31	5.02	5.61	*217*	4.58	4.38	4.78
R20	*191*	4.23	4.01	4.45	*217*	3.73	3.57	3.89
R5-R20	*191*	1.09	0.93	1.25	*217*	0.85	0.75	0.96
X5	*191*	-1.66	-1.82	-1.50	*217*	-1.22	-1.32	-1.11
Ax	*188*	7.53	6.37	8.75	*213*	5.02	4.29	5.77
Fres	*190*	14.36	13.57	15.16	*216*	13.10	12.43	13.78

Note: means are geometric means of raw IOS values. The *n* values differ slightly because of missing data. R5=resistance at 5Hz, R20=resistance at 20Hz, R5-R20= difference between R5 and R20, X5= reactance at 5Hz, AX= area under the reactance curve between 5 and Fres, Fres= Resonant frequency.
Never smokers did not report any life-time cannabis or tobacco use (joint-years and pack-years both =0)

Supplementary Table 3: Pre- and Post- Salbutamol IOS Spearman Correlations in Women at age 45.

	R5	R20	R5-R20	X5	AX
Pre-Salbutamol (n=436)					
R20	0.85				
p	*<0.001*				
R5-R20	0.54	0.07			
p	*<0.001*	*0.14*			
X5	0.65	0.38	0.68		
p	*<0.001*	*<0.001*	*<0.001*		
AX	0.66	0.26	0.91	0.89	
p	*<0.001*	*<0.001*	*<0.001*	*<0.001*	
Fres	0.57	0.17	0.92	0.74	0.94
p	*<0.001*	*<0.001*	*<0.001*	*<0.001*	*<0.001*
Post-Salbutamol (n=433)					
R20	0.85				
p	*<0.001*				
R5-R20	0.42	-0.05			
p	*<0.001*	*0.31*			
X5	0.44	0.26	0.42		
p	*<0.001*	*<0.001*	*<0.001*		
AX	0.51	0.16	0.78	0.69	
p	*<0.001*	*<0.001*	*<0.001*	*<0.001*	
Fres	0.43	0.01	0.91	0.56	0.89
p	*<0.001*	*0.81*	*<0.001*	*<0.001*	*<0.001*

Coefficient *rho* statistics are for correlations between log transformed variables.
R5=resistance at 5Hz, R20=resistance at 20Hz, R5-R20= difference between R5 and R20, X5= reactance at 5Hz, AX= area under the reactance curve, Fres= Resonant frequency.

Supplementary Table 4: Pre- and Post- Salbutamol IOS Spearman Correlations in Men at age 45.

	R5	R20	R5-R20	X5	AX
Pre-Salbutamol (n=449)					
R20	0.88				
p	*<0.001*				
R5-R20	0.53	0.12			
p	*<0.001*	*0.01*			
X5	0.62	0.38	0.65		
p	*<0.001*	*<0.001*	*<0.001*		
AX	0.60	0.24	0.90	0.86	
p	*<0.001*	*<0.001*	*<0.001*	*<0.001*	
Fres	0.52	0.15	0.93	0.72	0.95
p	*<0.001*	*<0.001*	*<0.001*	*<0.001*	*<0.001*
Post-Salbutamol (n=443)					
R20	0.93				
p	*<0.001*				
R5-R20	0.33	-0.01			
p	*<0.001*	*0.85*			
X5	0.34	0.20	0.45		
p	*<0.001*	*<0.001*	*<0.001*		
AX	0.39	0.12	0.80	0.79	
p	*<0.001*	*0.01*	*<0.001*	*<0.001*	
Fres	0.30	0.01	0.89	0.61	0.93
p	*<0.001*	*0.90*	*<0.001*	*<0.001*	*<0.001*

Coefficient *rho* statistics are for correlations between log transformed variables.
R5=resistance at 5Hz, R20=resistance at 20Hz, R5-R20= difference between R5 and R20, X5= reactance at 5Hz, AX= area under the reactance curve, Fres= Resonant frequency.

Supplementary Table 5: Adjusted associations of cannabis and tobacco with post-bronchodilator IOS measures for the whole sample.

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
	n	874	874	874	874	859	862
Joint Years	*β*	0.067	0.056	0.026	0.020	0.056	0.069
	95% CI	*-0.003-0.138*	*-0.018-0.130*	*-0.039-0.092*	*-0.053-0.092*	*-0.014-0.125*	*-0.001-0.139*
	p	*0.061*	*0.137*	*0.431*	*0.594*	*0.114*	*0.055*
Pack Years	*β*	**0.111**	**0.086**	**0.070**	**0.086**	**0.078**	**0.089**
	95% CI	*0.041-0.182*	*0.12-0.160*	*0.004-0.135*	*0.013-0.158*	*0.008-0.147*	*0.018-0.159*
	p	*0.002*	*0.022*	*0.037*	*0.021*	*0.028*	*0.014*
Interaction term[b]	*p*	*0.079*	*0.096*	*0.598*	*0.559*	*0.369*	*0.204*

[a] All IOS measures are log-transformed and analyses are adjusted for use of both substances and also adjusted for sex, BMI, and height; bolded values are statistically significant. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

[b] Interaction term p-values are for joint years by sex in the adjusted model for each IOS measure tested for after the adjusted model was run

Supplementary Table 6: Adjusted associations of cannabis and tobacco with post-bronchodilator IOS measures stratified by sex.

		IOS Measures[a]					
		R5	R20	R5-R20	X5	AX	Fres
Women	n	433	433	433	433	427	428
Joint-years	*β*	**0.134**	**0.152**	-0.013	0.074	0.094	0.082
	95% CI	*0.009-0.260*	*0.021-0.283*	*-0.146-0.120*	*-0.061-0.208*	*-0.025-0.214*	*-0.047-0.210*
	p	*0.036*	*0.023*	*0.848*	*0.281*	*0.121*	*0.212*
Pack-years	*β*	**0.118**	0.053	**0.157**	0.034	0.062	**0.134**
	95% CI	*0.004-0.232*	*-0.066-0.171*	*0.036-0.277*	*-0.088-0.156*	*-0.045-0.169*	*0.018-0.251*
	p	*0.042*	*0.384*	*0.011*	*0.582*	*0.257*	*0.024*
Men	n	441	441	441	441	432	434
Joint-years	*β*	0.038	0.013	0.047	-0.006	0.038	0.064
	95% CI	*-0.048-0.124*	*-0.077-0.104*	*-0.019-0.114*	*-0.091-0.079*	*-0.050-0.125*	*-0.019-0.146*
	p	*0.382*	*0.772*	*0.161*	*0.891*	*0.398*	*0.130*
Pack-years	*β*	**0.102**	**0.101**	0.015	**0.115**	0.086	0.058
	95% CI	*0.011-0.192*	*0.005-0.197*	*-0.055-0.085*	*0.026-0.205*	*-0.007-0.178*	*-0.030-0.145*
	p	*0.028*	*0.038*	*0.678*	*0.012*	*0.070*	*0.194*

[a] All IOS measures are log-transformed and analyses are adjusted for use of both substances and also adjusted for BMI and height; bolded values are statistically significant. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

Supplementary Table 7: Adjusted associations of cannabis use with pre-bronchodilator IOS measures among the sub-sample who never used tobacco.

		IOS Measures[a]					
Pre-bronchodilator		R5	R20	R5-R20	X5	AX	Fres
	n	425	425	425	424	423	424
Joint Years	*β*	0.084	0.032	0.114	0.010	0.112	0.148
	95% CI	*-0.094-0.261*	*-0.159-0.223*	*-0.056-0.284*	*-0.143-0.164*	*-0.053-0.277*	*-0.25-0.320*
	p	*0.355*	*0.741*	*0.187*	*0.894*	*0.183*	*0.094*

[a] All IOS measures are log-transformed and analyses are adjusted for adjusted for sex, BMI, and height. *β* values are standardised regression coefficients, which represent the stardard deviation difference in IOS measure associated with each standard deviation change in joint- or pack-years.

Supplementary Table 8: Associations of cannabis and tobacco with pre-bronchodilator IOS measures for the whole sample adjusted for childhood and adult socio-economic status.

		IOS Measures[a]					
Pre-bronchodilator		R5	R20	R5-R20	X5	AX	Fres
	n	873	873	873	872	864	866
Joint Years	*β*	**0.098**	0.073	**0.076**	**0.106**	**0.122**	**0.119**
	95% CI	*0.026-0.170*	*-0.003-0.148*	*0.002-0.149*	*0.038-0.175*	*0.051-0.193*	*0.048-0.191*
	p	*0.008*	*0.058*	*0.043*	*0.002*	*0.001*	*0.001*
Pack Years	*β*	0.023	-0.007	0.054	0.043	0.036	0.015
	95% CI	*-0.051-0.098*	*-0.085-0.072*	*-0.022-0.131*	*-0.028-0.114*	*-0.038-0.110*	*-0.059-0.090*
	p	*0.540*	*0.869*	*0.160*	*0.236*	*0.346*	*0.689*

[a] All IOS measures are log-transformed and analyses are adjusted for use of both substances and also adjusted for sex, BMI, height, average SES from birth to 15 and SES at age 45; bolded values are statistically significant

Supplementary Table 9: Adjusted associations of cannabis use with pre-bronchodilator IOS measures among the sub-sample who never reported asthma.

		IOS Measures[a]					
Pre-bronchodilator		R5	R20	R5-R20	X5	AX	Fres
	n	603	603	603	602	596	597
Joint Years	*β*	**0.135**	**0.100**	**0.111**	**0.111**	**0.144**	**0.156**
	95% CI	*0.047-0.223*	*0.004-.0196*	*0.026-0.197*	*0.03-0.191*	*0.063-0.225*	*0.073-0.239*
	p	*0.003*	*0.041*	*0.011*	*0.007*	*0.001*	*<0.001*
Pack-years	*β*	0.025	0.015	0.041	0.002	0.016	0.018
	95% CI	*-0.062-0.113*	*-0.081-0.110*	*-0.044-0.126*	*-0.077-0.082*	*-0.066-0.098*	*-0.065-0.101*
	p	*0. 571*	*0.763*	*0.342*	*0.952*	*0.694*	*0.671*

[a] All IOS measures are log-transformed and analyses are adjusted for adjusted for sex, BMI, and height as well as both substances; bolded values are statistically significant.